Richard M Bergenstal Selected Research

Insulin Glargine (Lantus)

11/2021	Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia.
1/2021	Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial.
11/2020	Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy.
4/2019	EVALUATION OF INSULIN GLARGINE AND EXENATIDE ALONE AND IN COMBINATION: A RANDOMIZED CLINICAL TRIAL WITH CONTINUOUS GLUCOSE MONITORING AND AMBULATORY GLUCOSE PROFILE ANALYSIS.
1/2019	Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring.
1/2018	Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).
10/2017	Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.
4/2017	Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections.
1/2017	Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972-1980.
11/2016	Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard M Bergenstal Research Topics

Disease

66	Type 2 Diabetes Mellitus (MODY) 01/2022 - 08/2005
47	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2022 - 04/2005
37	Hypoglycemia (Reactive Hypoglycemia) 01/2022 - 08/2005
9	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2022 - 12/2012
8	Hyperglycemia 01/2022 - 04/2015
8	Weight Loss (Weight Reduction) 04/2019 - 03/2008
7	Weight Gain 04/2019 - 03/2008
7	Acute Coronary Syndrome 08/2018 - 10/2011
7	Body Weight (Weight, Body) 10/2017 - 03/2008
4	Stroke (Strokes) 11/2019 - 01/2016
4	Myocardial Infarction 11/2019 - 10/2013
4	Obesity 10/2017 - 06/2009
4	Pancreatitis 01/2016 - 07/2011
4	Neoplasms (Cancer) 10/2013 - 07/2010
3	Ketosis 01/2022 - 04/2015
3	Heart Failure 11/2019 - 01/2016
3	Cardiovascular Diseases (Cardiovascular Disease) 04/2016 - 11/2013
3	Inflammation (Inflammations) 07/2015 - 07/2011
3	Overweight 11/2013 - 03/2008
3	Nausea 01/2011 - 05/2010
2	Coma (Comas) 04/2021 - 12/2012
2	Diabetes Complications 01/2021 - 11/2018
2	Insulin Resistance 12/2018 - 09/2009
2	Unstable Angina 08/2018 - 10/2013
2	Coronary Disease (Coronary Heart Disease) 01/2017 - 01/2016
2	Pain (Aches) 03/2015 - 04/2003
1	Bone Fractures (Bone Fracture) 11/2019
1	Belonephobia 01/2019
1	Chronic Kidney Failure (Chronic Renal Failure) 04/2016
1	Obstructive Sleep Apnea 01/2016
1	Sleep Apnea Syndromes (Sleep Apnea) 01/2016
1	Infections 07/2015
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 06/2014
1	Kidney Diseases (Kidney Disease) 10/2013
1	Injection Site Reaction 12/2012

Drug/Important Bio-Agent (IBA)

64	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 09/2005
63	Insulin (Novolin)FDA Link 01/2022 - 04/2005
24	Insulin Glargine (Lantus)FDA Link 11/2021 - 03/2008
16	Hypoglycemic Agents (Hypoglycemics)IBA 01/2022 - 08/2005
14	Metformin (Glucophage)FDA LinkGeneric 01/2022 - 03/2008
12	Blood Glucose (Blood Sugar)IBA 01/2022 - 04/2003
11	Exenatide (Byetta)FDA Link 04/2019 - 03/2008
9	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 04/2016 - 04/2005
7	alogliptinIBA 08/2018 - 10/2011
6	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2022 - 06/2009
5	IncretinsIBA 01/2022 - 06/2009
5	Liraglutide FDA Link 01/2016 - 06/2009
4	insulin degludecIBA 01/2022 - 09/2013
4	Peptides (Polypeptides)IBA 01/2022 - 06/2009
4	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2022 - 12/2012
4	lixisenatideIBA 10/2017 - 11/2016
4	LY2605541IBA 01/2014 - 11/2012
4	Sitagliptin Phosphate (Januvia)FDA Link 12/2012 - 06/2009
3	Glucagon-Like Peptide-1 ReceptorIBA 01/2022 - 07/2011
3	InsulinsIBA 01/2021 - 12/2015
3	Hemoglobins (Hemoglobin)IBA 04/2019 - 09/2005
2	Short-Acting InsulinIBA 04/2021 - 01/2016
2	omega-Chloroacetophenone (Mace)IBA 11/2019 - 01/2017
2	C-PeptideIBA 12/2016 - 04/2016
2	SuspensionsIBA 05/2015 - 07/2013
2	Pioglitazone (Actos)FDA Link 01/2011 - 08/2010
2	Biological ProductsIBA 07/2010 - 07/2010
2	Glucagon-Like Peptide-1 Receptor AgonistsIBA 07/2009 - 06/2009
2	VildagliptinIBA 07/2009 - 06/2009
2	CarbohydratesIBA 07/2008 - 04/2003
1	KetonesIBA 01/2022
1	DKA 9IBA 01/2022
1	tirzepatideIBA 01/2022
1	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022
1	insulin icodecIBA 01/2021
1	Insulin Lispro (Humalog)FDA Link 11/2020
1	empagliflozinIBA 11/2019
1	Sodium-Glucose Transport ProteinsIBA 04/2019
1	SolutionsIBA 03/2019
1	(L)-Isomer Glucose (L-Glucose)IBA 07/2017
1	Insulin Aspart (NovoLog)FDA Link 01/2017
1	DiamondIBA 01/2017
1	FructosamineIBA 04/2016
1	AlbuminsIBA 04/2016
1	Biomarkers (Surrogate Marker)IBA 04/2016
1	Oxygen (Dioxygen)IBA 01/2016
1	basal insulin peglisproIBA 01/2016
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2016
1	AS 8IBA 03/2015
1	Amylases FDA Link 11/2014
1	Lipase (Acid Lipase)FDA Link 11/2014
1	Long-Acting Insulin (Insulin, Long Acting)FDA Link 01/2014
1	Glucagon-Like Peptide ReceptorsIBA 11/2013
1	Pharmaceutical PreparationsIBA 11/2013
1	Cardiovascular AgentsIBA 10/2013
1	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 10/2013
1	taspoglutideIBA 12/2012
1	Isophane Insulin (NPH Insulin)FDA Link 11/2012
1	Hemoglobin AIBA 11/2012

Therapy/Procedure

36	Therapeutics 01/2022 - 08/2005
29	Glycemic Control 01/2022 - 08/2005
7	Injections 01/2021 - 07/2010
1	Ambulatory Care (Outpatient Care) 01/2021
1	Activities of Daily Living (ADL) 12/2016
1	Critical Care (Surgical Intensive Care) 07/2015